MedTrace Logo

Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

NCT06134635 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-11-18

No results posted yet for this study

Summary

This is a prospective cohort study to investigate the early impact of evolocumab on patients with acute ischemic stroke (AIS) in China. Evolocumab, a proprotein convertase subtilisin/kexin taye 9 inhibitor, can significantly reduce low density lipoprotein cholesterol (LDL-C) levels and has a positive effect on improving cardiovascular events. However, existing studies have focused almost exclusively on the long-term effects of Evolocumab, and the early effects of Evolocumab on AIS patients remains unclear.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Statins

Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral

DRUG

Evolocumab

Evolocumab 140mg twice a month, subcutaneous injection

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Meng Ran, PhD · Xuanwu Hospital, Beijing

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-11-01
Completion
2024-12-01
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06134635 on ClinicalTrials.gov